Hospital Acquired Infection Control Market Size, Share, and Growth Forecast 2026-2033

The global hospital acquired infection control market size is likely to be valued at US$24.1 billion in 2026 and projected to reach US$38.7 billion by 2033, growing at a CAGR of 7.0% during the forecast period between 2026 and 2033, driven by rising hospital admission volumes and stricter infection prevention protocols.

Healthcare facilities are increasing investment in sterilization equipment and automated endoscope reprocessing to reduce cross-contamination risk. Growing surgical procedure volumes are lifting demand for protective barriers and cleaning products across operating rooms.

Driver - Rising Surgical Volumes and Stricter Infection Prevention Protocols

Rising surgical procedure volumes are a core driver of the hospital-acquired infection control market. Growing numbers of inpatient and outpatient surgeries increase exposure to bloodstream and surgical site infections, pushing hospitals to expand sterilization and disinfection capacity. Regulatory bodies, including the U.S. Centers for Disease Control and Prevention, continue to publish updated infection prevention guidelines that hospitals must follow to maintain accreditation and reimbursement eligibility. Compliance requirements are prompting healthcare facilities to standardize cleaning protocols and invest in validated sterilization equipment.

Growing use of flexible endoscopes in gastrointestinal and pulmonary procedures is also increasing demand for automated endoscope reprocessing systems, which reduce the risk of improperly cleaned instruments. Expanding hospital infrastructure across emerging economies is adding new demand for protective barriers, disinfectants, and sterilization capital equipment. Rising awareness of antimicrobial resistance is further encouraging healthcare systems to prioritize infection prevention spending over reactive treatment costs.

Restraint - High Equipment Costs and Workforce Training Requirements

Advanced sterilization and endoscope reprocessing equipment require significant upfront capital investment, which can limit adoption among smaller hospitals and clinics with constrained budgets. Ongoing maintenance and validation testing add further operating costs for healthcare facilities.

Effective infection control also depends on consistent staff training and protocol adherence. Staffing shortages in sterile processing departments can lead to procedural inconsistencies, undermining the effectiveness of even well-equipped facilities. Meeting differing regulatory standards across countries further complicates product standardization for manufacturers operating internationally.

Opportunity - Growth in Automated Reprocessing and Rapid Diagnostic Technologies

Growing adoption of automated endoscope reprocessing systems is opening new opportunities, as hospitals seek to reduce manual handling errors and increase processing throughput. Manufacturers are investing in systems with independent monitoring and validated cleaning cycles to meet rising demand from high-volume endoscopy departments.

Rapid molecular diagnostic technologies for detecting hospital-acquired pathogens are also creating new avenues for growth, enabling faster clinical response and reduced infection transmission. Expanding ambulatory surgical center networks across North America and Europe is increasing demand for compact, efficient infection control solutions designed for smaller facility footprints.

Infection Type Insights

Surgical site infections are estimated to lead the infection type segment, capturing around 50% of market share in 2026, fueled by the high volume of invasive procedures performed across hospitals and surgical centers worldwide. Their association with extended hospital stays and higher treatment costs keeps prevention spending concentrated in this category.

Bloodstream infections are likely to be the fastest-growing segment through 2033. Rising use of intravenous catheters and central lines in critical care settings is increasing exposure risk, driving stronger demand for advanced barrier and disinfection protocols in intensive care units.

Products & Services Insights

Cleaning and disinfection products are expected to dominate the products and services segment, holding around 32% of market share in 2026. Their routine, recurring use across all hospital departments supports steady, high-volume demand.

Endoscope reprocessing products are likely to be the fastest-growing. Rising gastrointestinal and pulmonary procedure volumes, combined with stricter reprocessing validation requirements, are driving hospitals to upgrade to automated, higher-throughput reprocessing systems.

End-user Insights

Hospitals and clinics are anticipated to dominate the end-user segment, accounting for nearly 68% of market share in 2026. Their high patient volumes and broad range of surgical and diagnostic procedures sustain this leadership across both developed and emerging markets.

Surgical centers are likely to be the fastest-growing segment. Rising preference for outpatient procedures and expanding ambulatory surgical center networks are driving faster growth in this segment compared with traditional hospital settings.

North America Hospital Acquired Infection Control Market Trends

North America is forecast to lead the regional market, capturing around 37% of hospital-acquired infection control market revenue in 2026. Strict regulatory oversight and well-established reimbursement frameworks support strong adoption of advanced sterilization and disinfection technologies. The presence of leading infection control manufacturers and academic medical centers strengthens the region's market position. Growing investment in ambulatory surgical infrastructure is adding further momentum.

U.S. Hospital Acquired Infection Control Market Trends

The U.S. is projected to account for close to 88% of the North American market share in 2026. Stringent Centers for Disease Control and Prevention guidelines, high surgical procedure volumes, and continued investment in automated reprocessing technology support demand. Rising adoption of rapid diagnostic testing for hospital-acquired pathogens is also shaping the market.

Canada Hospital Acquired Infection Control Market Trends

Canada is expected to hold close to 12% of the North American market share in 2026. Growing investment in public hospital infrastructure and rising focus on antimicrobial stewardship programs are supporting demand for infection control products across the country.

Europe Hospital Acquired Infection Control Market Trends

Europe is estimated to account for approximately 26% of market revenue in 2026. Strong regulatory frameworks under the European Union’s medical device rules, along with an aging population and rising chronic disease prevalence, are supporting demand for validated sterilization and disinfection systems. European healthcare facilities adhere to stringent regulatory and quality standards, further driving the adoption of advanced infection control solutions.

Germany Hospital Acquired Infection Control Market Trends

Germany is projected to lead within Europe, holding close to 24% of the regional market share in 2026. A large hospital network and strong medical device manufacturing base support demand for sterilization and reprocessing equipment. Continued investment in hospital infrastructure modernization adds further support.

U.K. Hospital Acquired Infection Control Market Trends

The U.K. is expected to hold around 18% of the European market share in 2026. Growth is supported by National Health Service infection prevention initiatives and rising surgical procedure backlogs. Increasing focus on reducing hospital-acquired bloodstream infections is shaping procurement decisions among healthcare trusts.

Asia Pacific Hospital Acquired Infection Control Market Trends

Asia Pacific is likely to be the fastest-growing regional market, expanding at a CAGR of approximately 8.2% from 2026 to 2033. Hospital infrastructure is expanding across the region. China and India are adding new healthcare facilities. Southeast Asian countries are also strengthening healthcare systems. Surgical procedures are increasing across major Asian markets. More surgeries create a greater need for sterilization and disinfection products. Governments are also increasing healthcare investment. For example, India allocated ?64,180 crores under PM-ABHIM to strengthen public health infrastructure. https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2182105&reg=48&lang=2

China Hospital Acquired Infection Control Market Trends

China is projected to dominate Asia Pacific, accounting for close to 36% of market share in 2026. China continues to expand its hospital infrastructure. Government healthcare spending is also increasing. Rising healthcare spending and hospital infrastructure expansion are supporting the development of new and upgraded medical facilities. The country is also strengthening domestic medical device production. This supports local access to infection-control equipment. It also reduces dependence on imported products.

India Hospital Acquired Infection Control Market Trends

India is expected to be the fastest-growing country market in Asia Pacific. It is projected to hold nearly 19% of the regional share in 2026. Hospital capacity is expanding across the country. Private healthcare companies are also investing in new facilities. For example, Manipal Health planned to add 2,400 beds across its network. Medical tourism is also receiving policy support. The 2026–27 Union Budget proposed five regional medical hubs with private-sector participation. Government spending on healthcare infrastructure is increasing. The 2026–27 budget raised funding for PM-ABHIM to ?4,770 crores. This supports hospitals, laboratories, and critical-care facilities.

The global hospital acquired infection control market is moderately consolidated, led by diversified medical technology companies with broad sterilization, disinfection, and diagnostic portfolios. STERIS plc, Getinge AB, and Olympus Corporation represent leading market participants, competing on product breadth, validated reprocessing technology, and global service infrastructure across hospitals and surgical centers. Cantel Medical, Belimed, and STEELCO S.p.A. continue to strengthen their presence in endoscope reprocessing and sterilization equipment.

BD, 3M, and Diversey Inc. maintain strong positions in protective barriers and cleaning and disinfection products used across hospital departments. ASP, Crosstex International Inc., and MMM Group continue to expand their sterilization and infection prevention portfolios. bioMérieux SA, Cepheid, Sterigenics U.S. LLC, Dentsply Sirona, Mindray Bio-Medical Electronics Co., Ltd, Randox Laboratories Ltd., Ortho Clinical Diagnostics, Nova Biomedical, and Sysmex Corporation support the market through rapid diagnostic testing and contract sterilization services. Competitive dynamics center on automating reprocessing workflows, expanding rapid pathogen detection capability, and broadening validated disinfection product lines for healthcare customers.

Key Industry Developments:

• In July 2025, Getinge and Zimmer Biomet announced a strategic partnership to distribute Getinge’s operating room capital products to ambulatory surgery center customers. The partnership combined Getinge’s infection-control and surgical portfolio with Zimmer Biomet’s implants and surgical robotics through a single source.
• In January 2025, Olympus issued a voluntary advisory notice for its MAJ-891 Forceps/Irrigation Plug. The company warned that improper reprocessing could lead to device contamination and advised healthcare providers to follow appropriate reprocessing procedures.